0.1583
전일 마감가:
$0.171
열려 있는:
$0.168
하루 거래량:
1.93M
Relative Volume:
0.51
시가총액:
$10.00M
수익:
-
순이익/손실:
$-28.53M
주가수익비율:
-0.0889
EPS:
-1.7805
순현금흐름:
$-20.10M
1주 성능:
+4.01%
1개월 성능:
-41.80%
6개월 성능:
-68.92%
1년 성능:
-94.18%
Medicus Pharma Ltd Stock (MDCX) Company Profile
명칭
Medicus Pharma Ltd
전화
610-540-7515
주소
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
MDCX
Medicus Pharma Ltd
|
0.1582 | 10.27M | 0 | -28.53M | -20.10M | -1.7805 |
|
LLY
Lilly Eli Co
|
1,167.64 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
|
JNJ
Johnson Johnson
|
268.06 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
|
ABBV
Abbvie Inc
|
266.12 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
MRK
Merck Co Inc
|
152.10 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
|
NVS
Novartis Ag Adr
|
141.25 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria
Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia
Medicus Pharma officers receive restricted shares in lieu of cash bonuses By Investing.com - Investing.com South Africa
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative
FDA authorizes the next study of a skin cancer patch - Stock Titan
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - Stock Titan
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - Stock Titan
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - Stock Titan
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com Nigeria
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
MDCX Should I Buy - Intellectia AI
Medicus Pharma Ltd. Common Stock (NASDAQ: MDCX) Stock Price, News & Analysis - Kalkine
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
Medicus Pharma Secures Global Rights to Pfizer’s CD228V with $12M Initial Payment and $15M Commitment - kalkinemedia.com
$Medicus Pharma (MDCX.US)$ - Moomoo
Medicus Pharma inks deal with Pfizer to advance clinical-stage ADC - The Pharma Letter
Pfizer, Medicus ink licensing deal worth up to $1B (PFE:NYSE) - Seeking Alpha
Medicus Pharma Signs Potential $1B Deal to License Pfizer’s Cancer Drug CD228V - Minichart
Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate - Seeking Alpha
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin - TMX Newsfile
Medicus Pharma Warrant (MDCXW) Holds Steady at $0.33 as Trading Range TightensRVOL Breakout - vinanet.vn
Medicus Pharma Ltd. Warrant (MDCXW) Holds at $0.33 as Tight Trading Range PersistsVolume Gap - siam.in
Medicus (MDCX) Update: Slides 0.15% to $0.27 in the Latest Reading; Range Check - vinanet.vn
Medicus (MDCXW) Session: Ends a Quiet Session at $0.33 for the Current Session; Range Check: the Current Price Sits Inside the Supplied Technical Range in the Available RecordStock News - vinanet.vn
Medicus (MDCXW) Shares: Records a Muted Move to $0.33 in the Latest Session; Price Setup: Price Remains Between $0.31 Support and $0.35 Resistance in the Current UpdateCall Spread Alert - vinanet.vn
Medicus (MDCX) Quarterly Figures: The EPS Result Is Below Expectation in the Available Record; The Market Price Advances 1.15%Earnings Call Highlights - vinanet.vn
A. G. P. Maintains Medicus Pharma(MDCX.US) With Buy Rating, Cuts Target Price to $0.9 - Moomoo
Medicus Pharma on Bloomberg World - Coldwater Daily Reporter
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - dailyrecord.com
Top Medicus Pharma (MDCXW) Competitors 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Market movers: Cisco, Cerebras, Medicus Pharma, Ideal Power... - Proactive financial news
Medicus Pharma Ltd (MDCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):